Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181754 | 1.00 | MAPK1 (0.56) | MAPK1TSHRTDP1 | |
| SCHEMBL4181748 | 1.00 | MAPK1 (0.56) | MAPK1TSHRTDP1 | |
| SCHEMBL12858723 | 0.83 | MAPK1 (0.60) | MAPK1 | |
| SCHEMBL13905994 | 0.82 | MAPK1 (0.37) | MAPK1TSHRTDP1 | |
| SCHEMBL11402881 | 0.80 | MAPK1 (0.36) | MAPK1TSHR | |
| SCHEMBL8888351 | 0.78 | MAPK1 (0.34) | MAPK1TSHR | |
| SCHEMBL11403500 | 0.78 | TSHR (0.37) | MAPK1TSHRTDP1 | |
| Propylene Glycol SCHEMBL28059743 | 0.77 | MAPK1 (0.85) | MAPK1TSHRTDP1 | |
| SCHEMBL24906146 | 0.77 | MAPK1 (0.48) | MAPK1 | |
| SCHEMBL12285564 | 0.76 | MAPK1 (0.52) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206174-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206174-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-09-04 | — | — | US | disclosed |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20090042888-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A | 2009-02-12 | — | — | US | disclosed |
| US-7115591-B2 | Pyridazinone compounds as cyclooxygenase [COX] 2 inhibitorsfor gastrointestinal disorders | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-7001895-B2 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LABORATORIES (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1124804-B1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LAB (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2004-08-12 | — | — | US | disclosed |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2003-12-04 | — | — | US | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | MAPK1 1120/4885TSHR 4232/4885TDP1 3644/4885 |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | MAPK1 1080/4885TSHR 4179/4885TDP1 3633/4885 |
| US-20090042888-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGIS, PTGS1, PTGS2 | MAPK1 1412/4885TSHR 4055/4885TDP1 3931/4885 |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | MAPK1 1080/4885TSHR 4179/4885TDP1 3633/4885 |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | AR, SHBG, ESRRA | MAPK1 4052/4885TSHR 819/4885TDP1 1847/4885 |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | MAPK1 1363/4885TSHR 2504/4885TDP1 288/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | MAPK1 1080/4885TSHR 4179/4885TDP1 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.